Hiba Therapeutics

A platform-based targeted strategy for solid cancers.

wefunder

Developing a modular, programmable platform to harness tumor-resident T cells against cancer. The approach is based on validated science from Harvard and Mass General, with research published in leading journals.

The description cites superior head-to-head efficacy against best-in-class PD-1 therapies for aggressive cancers. The lead asset, HIB 117, is described as well tolerated and safe, with no detectable toxicities.

The company is based in Kendall Square, Cambridge, Massachusetts, a biotech hub. It is supported by the AI BioHub Accelerator Program, LabCentral, and Biolabs Golden Ticket, among others.